Pipeline Insight: Schizophrenia

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-07-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards.


Scope

  • Detailed pipeline analysis for key products in development for schizophrenia, plus drug sales forecasts to 2015
  • Overview of patient potential, segmentation by indication and unmet needs in schizophrenia across the US, EU and Japan
  • Benchmarking of key product and company attractiveness of late-phase pipeline products
  • Detailed clinical trial information and opinions from key thought leaders


    • Report Highlights
    By 2015, prospective players can expect to face stiff competition from numerous generic atypical antipsychotics. Product differentiation through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential.

    Current schizophrenia drug manufacturers are taking measures to buffer the erosion of their products by generics over the forecast period. Of the current players, Datamonitor forecasts that only Pfizer will maintain a strong schizophrenia franchise after the genericization of its marketed drug, with the remaining franchises expected to decline.

    The potential of Organon/Pfizer's asenapine in treating negative symptoms will be a key therapeutic and commercial advantage, with the drug forecast to be the leading market entrant in terms of value by 2015. Lundbeck/Solvay/Wyeth's bifeprunox's will become the second highest new entrant in terms of value by 2015.


    Reasons to Purchase

  • Understand unmet needs in the schizophrenia market based on key opinion leader comments regarding both currently marketed and pipeline products
  • Benchmark key late-stage schizophrenia compounds against current market leaders
  • Assess the global sales forecasts of late-stage pipeline drugs for schizophrenia and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: Schizophrenia psychiatric antipsychotics psychosis pipeline schizophrenia antipsychotic japan sca136 sgs518 patent 2008 paliperidone asenapine

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.